Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ABC294640 + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ABC294640||Yeliva|Opaganib|ABC-294640|ABC 294640||Yeliva (ABC294640) is a selective inhibitor of sphingokinase 2 (SK2), which results in decreased SK2 activity, leading to reduced cell signaling and tumor cell growth (PMID: 26271487).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||not applicable||ABC294640 + Gemcitabine||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of ABC294640 and Gemzar (gemcitabine) worked synergistically to decrease viability of pancreatic cancer cell lines in culture (PMID: 27517489).||27517489|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|